Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and N‐terminal pro‐brain natriuretic peptide

Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and... INTRODUCTIONHeart failure (HF) is a pivotal public health issue which influences over 5.7 million American people and takes $37.2 billion every year and its morbidity reaches epidemic proportions. Moreover, it is evaluated that 45% of women and 59% of men die in 5 years after a HF diagnosis. Chronic HF (CHF) is a long‐term product of heart failure, is usually managed by treating symptoms and patients suffering from deteriorating symptoms and signs may need hospitalization or more frequent doctor visits. The most common causes of HF are as follow: coronary artery disease, high blood pressure, atrial fibrillation, previous myocardial infarction (heart attack), valvular heart disease, cardiomyopathy, infection, and excessive alcohol consumption. The prevalence and occurrence of HF progressively increases with age, with the most affected age group being over 50 years. In developed countries, 1%‐2% of the adult population suffers from HF, increasing to ≥10% for those older than 70 years. The National Institute for Health and Care Excellence (NICE) recommends measurement of brain natriuretic peptide combined with an ultrasound of the heart in the occurrence of symptom development. Up until now no elite diagnostic criterion has been established for HF.Suppression of tumorigenicity 2 (ST2), namely an interleukin (IL)‐33 related receptor, is http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Laboratory Analysis Wiley

Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and N‐terminal pro‐brain natriuretic peptide

Loading next page...
 
/lp/wiley/diagnosis-of-chronic-heart-failure-by-the-soluble-suppression-of-XGWiTPtT0H
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 Wiley Periodicals, Inc.
ISSN
0887-8013
eISSN
1098-2825
D.O.I.
10.1002/jcla.22295
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONHeart failure (HF) is a pivotal public health issue which influences over 5.7 million American people and takes $37.2 billion every year and its morbidity reaches epidemic proportions. Moreover, it is evaluated that 45% of women and 59% of men die in 5 years after a HF diagnosis. Chronic HF (CHF) is a long‐term product of heart failure, is usually managed by treating symptoms and patients suffering from deteriorating symptoms and signs may need hospitalization or more frequent doctor visits. The most common causes of HF are as follow: coronary artery disease, high blood pressure, atrial fibrillation, previous myocardial infarction (heart attack), valvular heart disease, cardiomyopathy, infection, and excessive alcohol consumption. The prevalence and occurrence of HF progressively increases with age, with the most affected age group being over 50 years. In developed countries, 1%‐2% of the adult population suffers from HF, increasing to ≥10% for those older than 70 years. The National Institute for Health and Care Excellence (NICE) recommends measurement of brain natriuretic peptide combined with an ultrasound of the heart in the occurrence of symptom development. Up until now no elite diagnostic criterion has been established for HF.Suppression of tumorigenicity 2 (ST2), namely an interleukin (IL)‐33 related receptor, is

Journal

Journal of Clinical Laboratory AnalysisWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial